Bal Pharma Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Mon Apr 13 2026

Bal Pharma (BALPHARMA) Q4 FY26 results are scheduled for May 15, 2026, when the company’s board of directors will approve the financial statements for the January-March 2026 quarter. Trading at Rs 148 as of April 2026 — down -32% from its 52-week high of Rs 228 — the stock has been under pressure alongside its peers in the Pharmaceuticals / Generics sector. This Q4 results preview covers the confirmed results date, analyst consensus estimates, five key performance factors, five risks to monitor, analyst ratings, and the complete share price outlook.

Bal Pharma’s Q4 FY26 earnings will be watched for signals on the company’s +10% revenue YoY trajectory, and whether operating metrics are recovering toward normalised levels. This article provides a structured preview based on analyst consensus data and publicly available financial information.

Get free investment predictions on Univest.

Table of Contents

Bal Pharma Q4 Results 2026 Date

The Bal Pharma Q4 FY26 results date is May 15, 2026. The board of directors will meet to approve the audited consolidated and standalone financial results for the quarter ended March 31, 2026, and the full year FY2025-26.

Here is a broader view of the Q4 FY26 results calendar for reference:

Company	Results Date	Key Metric
[object Object]	April 9, 2026 (Declared)	FY27 revenue guidance, deal TCV
[object Object]	April 23, 2026	CC growth guidance for FY27
Bharat Electronics (BEL)	May 8, 2026	Order book execution, EBITDA margin
Bharat Forge	May 10, 2026	Global CV + defence execution
Bal Pharma	May 15, 2026	See estimates below

Why Q4 FY26 Matters

Q4 (January-March) is the final quarter of FY26, making it the most important earnings event of the year. Beyond the quarterly numbers, investors will receive: full-year FY26 financial summary, management commentary on FY27 business outlook, and the final dividend recommendation for FY26 shareholders.

For Bal Pharma specifically, Q4 FY26 captures the peak season dynamics of the Pharmaceuticals / Generics sector. Management’s commentary on FY27 demand visibility will set the investment narrative for the next 12 months.

Bal Pharma Q4 FY26 Earnings Estimates

Bal Pharma Q4 FY26 analyst consensus estimates — Revenue, PAT, Margin

Access premium research on Univest.

Based on publicly available analyst consensus, here are the Q4 FY26 estimates for Bal Pharma:

Metric	Q4 FY26 Estimate	Q3 FY26 Actual	Trend
Revenue	Rs 285 Cr	Rs 258 Cr	QoQ expected improvement
Net Profit (PAT)	Rs 12 Cr	Rs 10 Cr	Normalisation expected
Margin	EBITDA 10%	Q3 FY26 margin	QoQ trend
Volume / Growth Driver	+10% revenue YoY	Prior quarter	YoY
Dividend (Expected)	Rs 0.50 (expected)	FY26 interim dividends	Final dividend

Screen Bal Pharma live fundamentals on the Univest Screener.

Download the Univest iOS App or Univest Android App for real-time Q4 result alerts and analyst updates.

5 Key Factors Driving Bal Pharma Q4 FY26 Performance

1. Branded Generic Domestic Growth

Bal Pharma’s India branded generic business across cardiovascular, anti-infective, and pain management therapeutic areas is growing at 8-10% annually in line with the IPM.

2. API Manufacturing

The company manufactures APIs for internal use and third-party customers. API segment margins are higher than finished dosage forms, and any new API customer wins would be positive.

3. Export Market Development

Bal Pharma has been developing export markets in Africa, Southeast Asia, and the Middle East for its generic formulations. Export revenue growth is incremental to domestic growth.

4. Field Force Productivity

Improving prescription productivity per medical representative is the primary lever for domestic revenue growth. Q4 management commentary on MR efficiency would be a quality indicator.

5. DRHP Filing

Any DRHP filing or corporate action announcement alongside Q4 results would be a market catalyst.

5 Risks to Watch in Bal Pharma Q4 FY26

Risk 1: IPM Slowdown

The Indian Pharmaceutical Market growing below 8% would impact Bal Pharma’s branded generic revenue.

Risk 2: FDA Regulatory Risk

Any FDA inspection observation on export facilities would create compliance costs and potential revenue disruption.

Risk 3: Competition from Generic Chains

Pharmacy chain private labels compete in the generic medicine segment, putting pressure on branded generic pricing.

Risk 4: Working Capital

Pharmaceutical distribution has long receivable cycles from distributors and government institutions.

Risk 5: Thin Margins

At 10% EBITDA, margin recovery to 12%+ requires revenue scale without proportionate cost increases.

Bal Pharma Share Price and Analyst Ratings

Parameter	Value
CMP (April 2026)	Rs 148
52-Week High	Rs 228
52-Week Low	Rs 128
1-Year Return	-32%
Market Capitalisation	Rs 380 Cr
Sector	Pharmaceuticals / Generics
NSE Ticker	BALPHARMA

Analyst ratings and target prices based on publicly available brokerage research:

Brokerage	Rating	Target Price	Investment Thesis
Geojit Financial	ADD	Rs 180	Branded generic growth on track
HDFC Securities	NEUTRAL	Rs 155	Scale needed for meaningful rerating

Conclusion

Bal Pharma Q4 FY26 will reflect India pharma market trends. Revenue above Rs 285 crore with PAT above Rs 12 crore would be a beat. The API and export segments are the incremental growth catalysts beyond domestic branded generics.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.

For more Q4 FY26 results previews, visit Univest Blogs.

Frequently Asked Questions

Q: When is Bal Pharma Q4 results 2026 date?

Bal Pharma Q4 FY26 results date is May 15, 2026. The board of directors will meet on this date to approve the quarterly and full-year FY26 financial results and consider recommending a final dividend.

Q: What is Bal Pharma Q4 FY26 revenue estimate?

Analyst consensus estimate for Bal Pharma Q4 FY26 revenue is Rs 285 Cr. Q3 FY26 actual revenue was Rs 258 Cr. Actual Q4 results may vary based on operating conditions.

Q: What is Bal Pharma Q4 FY26 PAT estimate?

Analyst consensus estimate for Bal Pharma Q4 FY26 net profit (PAT) is Rs 12 Cr. Q3 FY26 actual PAT was Rs 10 Cr. Estimates are indicative and not guaranteed.

Q: Will Bal Pharma declare a dividend in Q4 FY26?

Bal Pharma is expected to declare Rs 0.50 (expected) for FY26, subject to board approval at the May 15, 2026 board meeting and subsequent shareholder approval at the AGM.

Q: What is Bal Pharma current share price?

Bal Pharma is trading at Rs 148 as of April 2026, with a 52-week range of Rs 128 to Rs 228. The 1-year return is -32%.

Q: What were Bal Pharma Q3 FY26 results?

In Q3 FY26, Bal Pharma reported revenue of Rs 258 Cr and net profit (PAT) of Rs 10 Cr. The Q4 FY26 results on May 15, 2026 will provide a comparison to assess sequential and year-on-year trends.

Q: When do TCS and Infosys announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026 (see the Bal Pharma earnings calendar table above). Infosys is scheduled to declare results on April 23, 2026. Both are covered in detail on Univest Blogs.

Q: Is Bal Pharma a good investment ahead of Q4 results?

This article does not constitute investment advice. Bal Pharma trades at Rs 148 with a 52-week range of Rs 128 to Rs 228. Analyst consensus targets and the Q4 FY26 estimates suggest monitoring the results date closely. Consult a SEBI-registered financial advisor for personalised investment guidance.